Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ASTH
ASTH logo

ASTH Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Astrana Health Inc (ASTH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
39.190
1 Day change
2.70%
52 Week Range
40.130
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ASTH is not a clear buy right now for a beginner long-term investor with $50,000-$100,000. The stock has constructive analyst support and bullish moving averages, but momentum is mixed, there is no fresh news catalyst, and the proprietary signals do not show a buy trigger today. My direct view: hold, not buy now.

Technical Analysis

Current price is 39.84, essentially flat versus the prior close of 39.85, after a 2.89% regular-session gain. The trend structure is still bullish because SMA_5 > SMA_20 > SMA_200, which supports an uptrend. However, MACD histogram is -0.15 and negatively contracting, showing short-term momentum has weakened. RSI_6 at 76.891 is elevated, suggesting the stock has already moved up strongly and may be extended. Price is sitting just below R1 at 39.624 and near R2 at 40.6, with pivot support at 38.045. Overall technical picture: bullish longer-term trend, but near-term entry is not ideal.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is strongly bullish. Put-call open interest ratio of 0.1 and volume put-call ratio of 0.0 indicate calls dominate positioning, with very little bearish hedging. Call open interest (6571) is far above put open interest (644). Implied volatility is 46.17, above historical volatility 37.6, but IV rank is low at 1.59 and IV percentile is 0, suggesting options are not unusually expensive relative to recent ranges. Overall, options traders are leaning bullish.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
2
Buy
11

Positive Catalysts

  • Barclays upgraded ASTH to Overweight with a $50 target, citing improved value-based care outlook, stabilizing cost trends, and better 2027 Medicare Advantage rate expectations. Truist, TD Cowen, Needham, and Baird all raised targets recently, signaling broad analyst optimism. The company also appears to be benefiting from integration progress with Prospect and accelerating full-risk membership growth. Trading sentiment in options is bullish, and the stock remains in a technically supportive long-term uptrend.

Neutral/Negative Catalysts

  • No news in the recent week, so there is no fresh event-driven catalyst right now. Short-term momentum is softening as MACD is negative. RSI is elevated, which means the stock may already be stretched after the recent run. Hedge funds and insiders are neutral, so there is no strong ownership-based confirmation. The stock trend model suggests a 60% chance of a -2.08% move next day, which reduces urgency for a new entry today.

Financial Performance

Latest quarter financials were not provided due to a data error, so I cannot confirm the latest quarter season from the snapshot. However, analyst commentary references a Q1 earnings beat and reiterated guidance, which implies recent operating performance was better than expected and that growth/integration trends are improving. Based on the available information, recent financial momentum appears positive, especially around execution and margin outlook, but I cannot verify detailed revenue or earnings growth figures from the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment has turned more positive over the last month. Barclays upgraded ASTH to Overweight and lifted its target to $50 from $37; Truist raised its target to $47 and kept Buy; TD Cowen lifted its target to $45 and kept Buy; Needham raised to $41 and kept Buy; Baird raised to $45 and remains Outperform. The overall Wall Street view is constructive, with multiple firms highlighting better integration, improving cost trends, and margin upside. The bearish case is weak, but the recent price run means much of the optimism is already reflected in the share price.

Wall Street analysts forecast ASTH stock price to fall
8 Analyst Rating
Wall Street analysts forecast ASTH stock price to fall
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 38.160
sliders
Low
26
Averages
33.2
High
40
Current: 38.160
sliders
Low
26
Averages
33.2
High
40
Barclays
Equal Weight
to
Overweight
upgrade
$37 -> $50
AI Analysis
2026-05-26
Reason
Barclays
Price Target
$37 -> $50
AI Analysis
2026-05-26
upgrade
Equal Weight
to
Overweight
Reason
Barclays upgraded Astrana Health to Overweight from Equal Weight with a price target of $50, up from $37. The firm says the outlook for value-based care has \"materially improved in recent weeks driven by encouraging signs\" of stabilizing cost trends and a more favorable 2027 Medicare Advantage rate outcome. Astrana has room for multiple expansion as its executes on its integration of Prospect and accelerates full-risk membership growth, the analyst tells investors in a research note.
Truist
Buy
maintain
$38 -> $47
2026-05-14
Reason
Truist
Price Target
$38 -> $47
2026-05-14
maintain
Buy
Reason
Truist raised the firm's price target on Astrana Health to $47 from $38 and keeps a Buy rating on the shares. The firm is citing the company's Q1 earnings beat while also noting that its higher valuation target - enterprise value to expected EBITDA at 11-times vs.10-times prior - reflects its incremental positivity in Astrana's integration of Prospect, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ASTH
Unlock Now

People Also Watch